Motus GI (MOTS) 10-Q 12 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 06, 2021
Document Information Line Items
Entity Registrant Name	Motus GI Holdings, Inc.
Trading Symbol	MOTS
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		48,241,188
Amendment Flag	false
Entity Central Index Key	0001686850
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38389
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-4042793
Entity Address, Address Line One	1301 East Broward Boulevard
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	Ft. Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33301
City Area Code	954
Local Phone Number	541 8000
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 26,379	$ 20,819	[1]
Accounts receivable	73	35	[1]
Inventory	706	805	[1]
Prepaid expenses and other current assets	859	448	[1]
Total current assets	28,017	22,107	[1]
Fixed assets, net	1,451	1,178	[1]
Right-of-use assets	712	766	[1]
Other non-current assets	13	13	[1]
Total assets	30,193	24,064	[1]
Current liabilities:
Accounts payable and accrued expenses	2,150	2,333	[1]
Operating lease liabilities - current	261	238	[1]
Other current liabilities	7	60	[1]
Term debt, net of debt discount of $17 and $21, respectively	7,983	7,979	[1]
Total current liabilities	10,401	10,610	[1]
Contingent royalty obligation	1,734	1,617	[1]
Operating lease liabilities - non-current	467	547	[1]
Total liabilities	12,602	12,774	[1]
Commitments and contingent liabilities (Note 9)
Shareholders’ equity
Preferred Stock $0.0001 par value; 10,000,000 shares authorized; zero shares issued and outstanding			[1]
Common Stock $0.0001 par value; 115,000,000 shares authorized; 48,241,188 and 32,272,309 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	5	3	[1]
Additional paid-in capital	130,698	115,008	[1]
Accumulated deficit	(113,112)	(103,721)
Total shareholders’ equity	17,591	11,290	[1]
Total liabilities and shareholders’ equity	$ 30,193	$ 24,064	[1]
[1]	Derived from audited consolidated financial statements

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Term debt, net of debt discount (in Dollars)	$ 17	$ 21
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	115,000,000	115,000,000
Common stock, shares issued	48,241,188	32,272,309
Common stock, shares outstanding	48,241,188	32,272,309

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 100	$ 1	$ 151	$ 29
Operating expenses:
Cost of revenue - sales	42	10	70	40
Research and development	1,508	1,264	2,853	3,199
Sales and marketing	795	582	1,471	2,445
General and administrative	2,345	2,365	4,789	5,277
Total costs and expenses	4,690	4,221	9,183	10,961
Operating loss	(4,590)	(4,220)	(9,032)	(10,932)
Gain (loss) on change in estimated fair value of contingent royalty obligation	(37)	(76)	(117)	245
Finance expense, net	(117)	(119)	(234)	(231)
Foreign currency gain (loss)	2	5	(8)	(3)
Net loss	(4,742)	(4,410)	(9,391)	(10,921)
Deemed dividends from warrant issuance			(6,145)
Net loss attributable to common shareholders	$ (4,742)	$ (4,410)	$ (15,536)	$ (10,921)
Basic and diluted loss per common share:
Net loss (in Dollars per share)	$ (0.10)	$ (0.15)	$ (0.21)	$ (0.38)
Net loss attributable to common shareholders (in Dollars per share)	$ (0.10)	$ (0.15)	$ (0.34)	$ (0.38)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	47,732,674	28,846,881	45,493,776	28,832,296

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated deficit	Total
Balance at Dec. 31, 2019	$ 3	$ 102,789	$ (84,464)	$ 18,328
Balance (in Shares) at Dec. 31, 2019	28,811,087
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units (in Shares)	15,070
Share based compensation		804		804
Net loss			(6,511)	(6,511)
Balance at Mar. 31, 2020	$ 3	103,593	(90,975)	12,621
Balance (in Shares) at Mar. 31, 2020	28,826,157
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units (in Shares)	30,916
Share based compensation		678		678
Net loss			(4,410)	(4,410)
Balance at Jun. 30, 2020	$ 3	104,271	(95,385)	8,889
Balance (in Shares) at Jun. 30, 2020	28,857,073
Balance at Dec. 31, 2020	$ 3	115,008	(103,721)	11,290	[1]
Balance (in Shares) at Dec. 31, 2020	32,272,309
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units (in Shares)	65,915
Issuance of common shares upon exercise of warrants, net of financing costs of $366	$ 2	11,591		11,593
Issuance of common shares upon exercise of warrants, net of financing costs of $366 (in Shares)	14,267,250
Issuance of common stock for board of directors’ compensation		272		272
Issuance of common stock for board of directors’ compensation (in Shares)	173,554
Share based compensation		919		919
Net loss			(4,649)	(4,649)
Balance at Mar. 31, 2021	$ 5	127,790	(108,370)	19,425
Balance (in Shares) at Mar. 31, 2021	46,779,028
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units (in Shares)	53,081
Issuance of common shares upon exercise of warrants, net of financing costs of $366		1,826		1,826
Issuance of common shares upon exercise of warrants, net of financing costs of $366 (in Shares)	1,340,870
Issuance of common stock for board of directors’ compensation		19		19
Issuance of common stock for board of directors’ compensation (in Shares)	18,209
Issuance of common stock to consultants		53		53
Issuance of common stock to consultants (in Shares)	50,000
Share based compensation		1,010		1,010
Net loss			(4,742)	(4,742)
Balance at Jun. 30, 2021	$ 5	$ 130,698	$ (113,112)	$ 17,591
Balance (in Shares) at Jun. 30, 2021	48,241,188
[1]	Derived from audited consolidated financial statements

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Net of financing costs		$ 366
Net of issuance costs	$ 74

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021		Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,391)		$ (10,921)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	200		201
Amortization of debt issuance costs	4		21
(Gain) loss on change in estimated fair value of contingent royalty obligation	117		(245)
Share based compensation	1,929		1,457
Issuance of common stock for board of directors’ compensation	114
Issuance of common stock for consultants	53
Impairment of fixed assets			18
Non-cash operating lease expense	54		105
Changes in operating assets and liabilities:
Accounts receivable	(38)		71
Inventory	43		(311)
Prepaid expenses and other current assets	(366)		(654)
Accounts payable and accrued expenses	(204)		(975)
Operating lease liabilities - current and non-current	(57)		(104)
Other current liabilities	(53)		(10)
Net cash used in operating activities	(7,595)		(11,347)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(269)		(225)
Proceeds from sale of available-for-sale securities			8,203
Net cash provided by (used in) investing activities	(269)		7,978
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares	1,901
Proceeds from exercise and purchase of warrants	11,959
Financing fees	(436)		(34)
Net cash provided by (used in) financing activities	13,424		(34)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	5,560		(3,403)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	20,819	[1]	20,528
CASH AND CASH EQUIVALENTS AT END OF PERIOD	26,379		17,125
CASH PAID FOR:
Interest	222		209
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Common stock issued to settle accrued expenses for board of directors’ compensation	56
Common stock issued for prepaid board of directors’ compensation	121
Reclassification of inventory to fixed assets	56		170
Reclassification of prepaid expenses to fixed assets	75
Purchase of fixed assets in accounts payable and accrued expenses	73
Financing costs incurred but unpaid at period end	4
Financing fees extinguished previously included in accounts payable and accrued expenses			$ 200
[1]	Derived from audited consolidated financial statements

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Description of Business	Note 1 – Description of Business Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC., are collectively referred to as “Motus GI” or the “Company”. The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company began commercialization in the fourth quarter of 2019, with the first commercial placements of its second generation Pure-Vu System as part of its initial U.S. market launch targeting early adopter hospitals. The Company does not expect to generate significant revenue from product sales until the COVID-19 pandemic has fully subsided and it expands its commercialization efforts for the Pure-Vu System, which is subject to significant uncertainty.

Basis of Presentation and Going

Basis of Presentation and Going Concern	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Going Concern	Note 2 – Basis of Presentation and Going Concern The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2020 10-K filed with the SEC on March 16, 2021. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The December 31, 2020 balance sheet information was derived from the audited financial statements as of that date. To date, the Company has generated minimal revenues, experienced negative operating cash flows and has incurred substantial operating losses from its activities. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources, future product sales, and through the issuance of debt or equity. While the full impact of the COVID-19 pandemic continues to evolve, the financial markets have been subject to significant volatility that adversely impacts the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, potential disruptions in supply chains, mobility restraints, and changing priorities could also affect the Company’s ability to enter into key agreements. The outbreak and government measures taken in response to the pandemic have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as certain medical services and supplies, have spiked, while demand for other goods and services have fallen. The future progression of the outbreak and its effects on the Company’s business and operations are uncertain. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company’s research and development activities, including, for example, medical and laboratory supplies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak. These disruptions may negatively impact the Company’s sales, its results of operations, financial condition, and liquidity in 2021. The Company has financed its operations primarily through sales of equity-related securities. As of June 30, 2021, the Company had an accumulated deficit of $113,112, total current assets of $28,017 and total current liabilities of $10,401 resulting in working capital of $17,616. For the six months ended June 30, 2021 the Company incurred a net loss of $9,391. As of June 30, 2021, the Company had cash and cash equivalents of $26,379. As of June 30, 2021, under the terms of the loan agreement with Silicon Valley Bank (“SVB”), the Company was required to maintain unrestricted cash in accounts held at SVB of at least $10,000 (the “Liquidity Covenant”). As described in greater detail below, in connection with entering into the Kreos Loan Agreement, as defined in Note 12- Subsequent Events, we have terminated the SVB Loan Agreement as of July 16, 2021 and are no longer subject to the Liquidity Covenant. Such conditions, as well as the uncertainty of the impact of the COVID-19 pandemic, raise substantial doubts about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the six months ended June 30, 2021 are consistent with those discussed in Note 3 to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2021. Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue recognition Sales contracts executed for the second generation Pure-Vu System are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled to. The Pure-Vu System consists of a Workstation and single use disposable sleeves (“Disposables”). For contracts outside the scope of ASC 606, the Company determines income for proposed supply arrangements under 1) ASC 842 as it pertains to an embedded lease of the Workstation within a proposed supply arrangement and 2) ASC 606 for the sale of the Disposables within the proposed supply arrangement. The Company allocates the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier. During the three months ended June 30, 2021, the Company recognized revenue of $100, which primarily consisted of $72 in accordance with ASC 606 and $28 in accordance with ASC 842. During the three months ended June 30, 2020, the Company recognized revenue of $1 in accordance with ASC 606. During the six months ended June 30, 2021, the Company recognized revenue of $151, which primarily consisted of $108 in accordance with ASC 606 and $43 in accordance with ASC 842. During the six months ended June 30, 2020, the Company recognized revenue of $29 in accordance with ASC 606. Basic and diluted net loss per share Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period. Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend for the issuance of warrants during the three and six months ended June 30, 2021 of $0 and $6,145, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders. Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2021, and December 31, 2020, the Company had a full valuation allowance against its deferred tax assets. For the three and six months ended June 30, 2021 and 2020, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and six months ended June 30, 2021 and 2020, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses. Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its consolidated financial statements and disclosures. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”, or ASU 2019-12, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was adopted on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company’s financial position or results of operations. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s financial statements and disclosures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at June 30, 2021 and December 31, 2020: June 30, 2021 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,734 $ 1,734 December 31, 2020 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,617 $ 1,617 Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the six months ended June 30, 2021 was as follows: Fair Value Measurements of Contingent Royalty Obligation (Level 3) Balance at December 31, 2020 $ 1,617 Change in estimated fair value of contingent royalty obligation 117 Balance at June 30, 2021 $ 1,734 The contingent royalty obligation is re-measured at each balance sheet date using several assumptions, including the following: 1) estimated sales growth, 2) length of product cycle, 3) patent life, 4) discount rate (21% as of June 30, 2021 and December 31, 2020), and 5) rate of royalty payment (3% as of June 30, 2021 and December 31, 2020). In accordance with ASC-820-10-50-2(g), the Company performed sensitivity analyses of the liability, which was classified as a Level 3 financial instrument. The contingent royalty obligation estimate may be significantly impacted by changes in assumptions used in these analyses. For example, the Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $204 and a 2% increase in the discount rate would decrease the liability by approximately $144.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory is stated at lower of cost or net realizable value using the weighted average cost method and is evaluated at least annually for impairment. Write-downs for potentially obsolete or excess inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts. There were no inventory write-down charges for the three and six months ended June 30, 2021 and 2020. Inventory at June 30, 2021 and December 31, 2020 consisted of the following: June 30, December 31, Raw materials $ 273 $ 333 Work-in-process - 211 Finished goods 682 529 Inventory reserve (249 ) (268 ) Inventory, net $ 706 $ 805

Fixed Assets, Net

Fixed Assets, Net	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Fixed assets, net	Note 6 – Fixed assets, net Fixed assets, summarized by major category, consist of the following for the years ended: June 30, December 31, Office equipment $ 168 $ 167 Computers and software 303 299 Machinery 775 455 Lab and medical equipment 1,186 1,039 Leasehold improvements 186 185 Total 2,618 2,145 Less: accumulated depreciation and amortization (1,167 ) (967 ) Fixed assets, net $ 1,451 $ 1,178 Depreciation and amortization expense for the three and six months ended June 30, 2021 was $102 and $200, respectively. Depreciation and amortization expense for the three and six months ended June 30, 2020 was $125 and $201, respectively. The Company incurred a loss on the impairment of fixed assets in the amount of $9 and $18 for the three and six months ended June 30, 2020, respectively.

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	Note 7 – Leases The Company leases an office in Fort Lauderdale, Florida under an operating lease. The term expires November 2024. The annual base rent is subject to annual increases of 2.75%. As described within Note 10, the Company shares this space with a related party pursuant to the Shared Space Agreement, as defined below. The Company leases an office in Israel under an operating lease. The term expires on December 31, 2022. The annual base rent is subject to increases of 4%. The Company leases vehicles under operating leases that expire at various dates through 2022. Many of these leases provide for payment by the Company, as the lessee, of taxes, insurance premiums, costs of maintenance and other costs which are expenses as incurred. Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years. The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Three Months ended Six Months ended 2021 2020 2021 2020 Lease Cost Operating lease cost, net of related party license fee $ 32 $ 50 $ 64 $ 105 Variable lease cost 30 29 60 58 Total lease cost $ 62 $ 79 $ 124 $ 163 As of As of 2021 2020 Assets Operating lease, right-of-use- asset $ 712 $ 766 Liabilities Current Operating lease liabilities $ 261 $ 238 Non-current Operating lease liabilities, net of current portion 467 547 Total lease liabilities $ 728 $ 785 Other information: Weighted average remaining lease term - operating leases 2.89 years 3.33 years Weighted-average discount rate - operating leases 7.65 % 7.78 % The Company records operating lease payments to lease expense using the straight-line method. The Company’s lease expense was $62 and $124 for the three and six months ended June 30, 2021, included in general and administrative expenses which is net of the related party license fee of $47 and $94 for the three and six months ended June 30, 2021, respectively (see Note 10). The Company’s lease expense was $79 and $163 for the three and six months ended June 30, 2020, respectively, included in general and administrative expenses, which is net of the related party license fee of $44 and $79 for the three and six months ended June 30, 2020, respectively.

Term Debt

Term Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Term Debt	Note 8 – Term Debt On December 13, 2019 (the “Effective Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) for $8,000 (the “Term Debt”) with Silicon Valley Bank (the “Bank” or “SVB”). On April 10, 2020, the Company entered into a Deferral Agreement (the “Deferral Agreement”) with SVB, effective April 2, 2020, which amends certain provisions of the Loan and Security Agreement, between the Company and SVB. Pursuant to and among other changes effected by, the Deferral Agreement, as of April 2, 2020, the originally scheduled period of monthly interest-only payments under the Loan Agreement, and the originally scheduled maturity date of the Loan Agreement, have each been extended by six months. As a result, pursuant to the Deferral Agreement, the Loan Agreement now provides for monthly interest-only payments through June 30, 2022, followed by monthly payments of principal and interest until June 1, 2024. The Term Debt of $8,000 bears an interest rate equal to the greater of (i) one-half of one percent (0.50%) above the Prime Rate and (ii) five and one-half percent (5.50%). At June 30, 2021, the interest rate was 5.50%. The Term Debt is collateralized by substantially all assets of the Company. Additionally, the Company has pledged 65% of the outstanding capital stock in the Company’s foreign subsidiary, Motus GI Medical Technologies, Ltd., to collateralize the Term Debt. Interest payments have commenced on January 1, 2020, following each month until the maturity date. Principal payments will commence July 1, 2022 and continuing for 24 consecutive months thereafter. The Company may prepay all, but not less than all, of the outstanding principal balance of the Term Debt subject to prepayment premium of $240, plus all other sums, if any, that shall have become due and payable. The Company incurred $50 of debt issuance costs related to the Term Debt. For the three and six months ended June 30, 2021, $2 and $4 of debt issuance costs was amortized to interest expense, respectively, using the effective interest method. For the three and six months ended June 30, 2020, $2 and $21 of debt issuance costs was amortized to interest expense, respectively, using the effective interest method. The effective interest rate on the Term Debt for the three months ended June 30, 2021 was 5.69%. The Company accounts for its bank indebtedness at amortized cost. Further, under the terms of the agreement, the Company must maintain unrestricted cash in accounts with the Bank of at least $10,000. The covenant was met by the Company as of June 30, 2021. The Company’s cash forecast indicates that it will need to raise additional funds during 2021, which is part of the current operating plan, in order to meet this liquidity requirement covenant during the coming year. The Term Debt includes a subjective acceleration clause. The Company has been continuously evaluating the actual and potential business impacts related to the COVID-19 pandemic. In response to the pandemic, certain measures were taken by authorities that could result in adverse financial impacts to the Company, including requiring Company workers to stay home. The Company considered the probability of a further slow-down of its sales team and the related impact on the potential to trigger the Liquidity Covenant, along with the volatility of the capital markets, which could cause SVB to exercise the subjective acceleration clause in determining the classification of the Company’s Term Debt. When considering these factors, the Company determined the likelihood of acceleration could be probable as the pandemic continues, and therefore the Company has classified the Term Debt in current liabilities. Future maturities under the amended terms of the Term Debt are as follows: Years Ending December 31, Amount 2021 (remaining six months) $ - 2022 2,000 2023 4,000 2024 2,000 Total 8,000 Less unamortized debt issuance costs (17 ) Total Term Debt, less debt issuance costs $ 7,983 Term Loan Refinancing On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, Lender will provide the Company with access to term loans in an aggregate principal amount of up to $12,000 (the “Loan”). Please see Note 12- Subsequent Events for additional information regarding the Kreos Loan Agreement. On the Effective Date, the Company used a portion of the proceeds from the Loan to repay in full all amounts outstanding under, and discharge all obligations in respect of, the Loan Agreement, between the Company and Silicon Valley Bank. The payment amount of approximately $8,200 included a negotiated prepayment premium of $220 under the terms of the payoff arrangement with SVB. As a result, the SVB Loan Agreement, together with all documents and agreements executed in connection therewith, including the Liquidity Covenant, have terminated and all liens associated therewith have been released as of the Effective Date.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Royalties to the IIA The Company has received, and may receive in the future, grants from the Government of the State of Israel through the Israeli National Authority for Technical Innovation (the “IIA”) for the financing of a portion of its research and development expenditures pursuant to the Israeli Law for the Encouragement of Research, Development and Technological Innovation in Industry 5744-1984 (the “Research Law”), and the regulations previously promulgated thereunder, as well as the IIA’s rules and benefit tracks which apply to companies receiving IIA funding (collectively, including the Research Law, the “IIA Regulations”) The total amount that was received and recorded between the periods ending December 31, 2011 through 2016 was $1,332. No amounts were received during the three and six months ended June 30, 2021 and 2020. The Company has a contingent obligation to the IIA for the total amount received along with the accumulated LIBOR interest to date in the amount of $1,413 and $1,407 as of June 30, 2021 and December 31, 2020, respectively. This obligation is repaid in the form of royalties on revenues generated in any fashion from know-how developed using IIA grants, with a rate that is currently 4% (which may be increased under certain circumstances), up to 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grants received, plus interest at the rate of 12-month LIBOR. Repayment of the grants is contingent upon the successful completion of the Company’s R&D programs and generating sales. The Company has no obligation to repay these grants if the R&D program fails, is unsuccessful, or aborted, or if no sales are generated. The Company has recorded an immaterial expense for the three and six months ended June 30, 2021 and 2020, and an immaterial liability at June 30, 2021 and December 31, 2020. Royalty Payment Rights on Royalty Payment Rights Certificates The Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”), establishing the rights and preferences of the holders of the Series A Convertible Preferred Stock, including certain directors and officers of the Company (the “Royalty Payment Rights”). As set forth in the Certificate of Designation, the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of: ● 3% of net sales subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the Company’s 2017 private placement (the “2017 Private Placement”); and ● 5% of licensing proceeds subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the 2017 Private Placement. In addition, in connection with completion of the 2017 Private Placement, the Company issued the placement agent royalty payment rights certificates (the “Placement Agent Royalty Payment Rights Certificates”) which grants the placement agent, and its designees, the right to receive, in the aggregate, 10% of the amount of payments paid to the holders of the Series A Convertible Preferred Stock, or the holders of the Royalty Payment Rights Certificates (the “Royalty Payment Rights Certificates”), upon the conversion of the Series A Convertible Preferred Stock into shares of the Company’s common stock. The Placement Agent Royalty Payment Rights Certificates are on substantially similar terms as the Royalty Payment Rights of the Series A Convertible Preferred Stock. The Royalty Payment Rights Certificate obligation and Placement Agent Royalty Payment Rights Certificate obligation (the “Contingent Royalty Obligation”) was recorded as a liability at fair value as “Contingent royalty obligation” in the consolidated balance sheets at June 30, 2021 and December 31, 2020 (see Contingent Royalty Obligation below). The fair value at inception was allocated to the royalty rights and the residual value was allocated to the preferred shares and recorded as equity. The Company amended its Certificate of Designation to modify the Royalty Payment Rights when the Company consummated its Initial Public Offering (“IPO”) on February 16, 2018, at which time the Company converted the Series A Convertible Preferred Stock into shares of the Company’s common stock and issued the Royalty Payment Rights Certificates. Pursuant to the terms of the Royalty Payment Rights Certificates, if and when the Company generates sales of the current and potential future versions of the Pure-Vu System, including disposables, parts, and services, or if the Company receives any proceeds from the licensing of the current and potential future versions of the Pure-Vu System, then the Company will pay to the holders of the Royalty Payment Rights Certificates a royalty (the “Royalty Amount”) equal to, in the aggregate, in royalty payments in any calendar year for all products: ● 3% of Net Sales* for commercialized product directly; and ● 5% of any Licensing Proceeds** for rights to commercialize the product if sublicensed by the Company to a third-party. * Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $20,000 (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Net Sales” is defined in the Royalty Payment Rights Certificates. The Company has not reached the Initial Net Sales Milestone as of June 30, 2021. ** Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Licensing Proceeds equal to $3,500 (the “Initial Licensing Proceeds Milestone”), and royalties shall only be computed on, and due with respect to, Licensing Proceeds in excess of the Initial Licensing Proceeds Milestone and (b) the total Licensing Proceeds based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Licensing” Proceeds is defined in the Royalty Payment Rights Certificate. The Company has not reached the Initial Licensing Proceeds Milestone as of June 30, 2021. The Royalty Amount will be payable up to the later of (i) the latest expiration date of the Company’s patents issued as of December 22, 2016, or (ii) the latest expiration date of any pending patents as of December 22, 2016 that have since been issued or may be issued in the future (which is currently May 2036). Following the expiration of all such patents, the holders of the Royalty Payment Rights Certificates and the holders of the Placement Agent Royalty Payment Rights Certificates will no longer be entitled to any further royalties for any period following the latest to occur of such patent expiration. On February 16, 2018, the date of the closing of the IPO, (1) the amendment to the Certificate of Designation became effective, (2) all outstanding shares of Series A Convertible Preferred Stock were converted into shares of the Company’s common stock pursuant to a mandatory conversion, and (3) the Royalty Payment Rights Certificates were issued to the former holders of the Series A Convertible Preferred Stock. Contingent Royalty Obligation The Contingent Royalty Obligation was recorded as a non-current liability at fair value in the consolidated balance sheets at June 30, 2021 and December 31, 2020 in the amount of $1,734 and $1,617, respectively. A loss on change in fair value of Contingent Royalty Obligation of $37 and $117 was recorded for the three and six months ended June 30, 2021, respectively. A loss on change in fair value of Contingent Royalty Obligation of $77 and a gain on change in fair value of Contingent Royalty Obligation of $245 was recorded for the three and six months ended June 30, 2020, respectively. Other Commitments and Contingencies The Company has a severance contingency for severance payments to its CEO, COO, and CFO in the aggregate of approximately $1,408, in the event that they are terminated without cause or leave due to good reason, as outlined in their employee agreements. Management estimates that the likelihood of payment is remote; therefore, no liability was reflected in these consolidated financial statements. Any serious disruption with the Company’s operations due to the COVID-19 outbreak could impair the Company’s ability to generate sufficient cash to repay its debt obligations when they become due and payable, either when they mature, or in the event of a default, which will cause the Company to breach its covenants and may negatively impact the Company’s business operations, financial condition, and results of operations. The Company is unable to predict the outcome of these matters and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from an unfavorable outcome.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 – Related Party Transactions Shared Space Agreement In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc., formerly a greater than 5% holder of the Company’s common stock and entity in which David Hochman, the Chairman of the Company’s board of directors, serves as the Chairman of the board of directors and Chief Executive Officer, and Darren Sherman, a member of the Company’s board of directors, serves as a director and as President and Chief Operating Officer. During the three and six months ended June 30, 2021, the Company recorded license fee of $47 and $94, respectively, in relation to the Shared Space Agreement. This amount is netted with rent expense in general and administrative expenses. During the three and six months ended June 30, 2020, the Company recorded license fee of $44 and $79, respectively, in relation to the Shared Space Agreement. This amount is netted with rent expense in general and administrative expenses. As of June 30, 2021 and December 31, 2020, the Company recorded a related party receivable of $2 and $0, respectively. Orchestra BioMed, Inc. will continue to pay a monthly license fee based on the shared space to the Company until the expiration of the Shared Space Agreement in September 2024. Aggregate license fees will range from $162 to $198 in any given calendar year during the term of the Shared Space Agreement.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Stock-based compensation	Note 11 – Stock-based compensation Issuance of Common Stock On January 13, 2021, the non-employee members of the Board of Directors were granted an aggregate of 52,317 fully vested shares of Common Stock as compensation, in lieu of cash compensation, for service as directors during the fourth quarter of 2020, pursuant to the Company’s non-employee director compensation policy. The Company recorded $56 in accrued expenses as of December 31, 2020 for director services during the three months ended December 31, 2020. The number of shares granted to the Company’s directors, in lieu of cash compensation, was determined by the dollar amount of quarterly fees due under the non-employee director compensation policy divided by the fair market value of a share of Common Stock as of the grant date which was $1.08. On February 17, 2021, the Company’s Compensation Committee approved a modification to the non-employee director compensation policy to permit payment of the fees for service as directors for 2021 in grants of the Company’s common stock, in lieu of cash compensation. Non-employee members of the Board of Directors were granted an aggregate of 121,237 fully vested shares of common stock at a price equal to $1.78 per share of common stock, as compensation, in lieu of $216 of cash compensation, for service as directors for 2021. On June 22, 2021, the Company granted to its newly appointed director an aggregate of 18,209 fully vested shares of common stock at a price equal to $1.04 per share of common stock, as compensation, in lieu of $19 of cash compensation, for service as a director for 2021. As of June 30, 2021, the Company recorded $121 in prepaid board of directors’ compensation. For the three and six months ended June 30, 2021, the Company recorded $60 and $114 of expense, respectively, in relation to the board of directors’ compensation. In March 2021, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) , or at- the- market offering, with Oppenheimer & Co. Inc. (“Oppenheimer”), under which it may offer and sell from time to time common shares having an aggregate offering price of up to $25,000. On April 30, 2021, the Company sold 1,340,870 shares of common stock pursuant to the above-described Equity Distribution Agreement, resulting in net cash proceeds of $1,826, after deducting issuance costs of $74. On May 17, 2021, we issued an aggregate of 50,000 fully vested shares of common stock to a consultant in consideration for services that were performed during the three months ended June 30, 2021 under a consulting agreement, with fair value of $53, based on a price of $1.06 per share of common stock, which was the closing price of the Company’s stock at the date of issuance. The Company recorded $53 of expense in the six months ended June 30, 2021, in relation to the consulting agreement. Issuance of Warrants to Purchase Common Stock On February 6, 2020, the Company entered into a services agreement whereby it agreed to issue warrants to purchase 120,000 shares of common stock of the Company. The warrants will vest over a one-year period on a monthly basis and expire three years from the date of issuance. 60,000 of the granted warrants are exercisable at a price equal to $2.16 per share of common stock and 60,000 of the remaining warrants granted are exercisable at a price equal to $3.50 per share of common stock. The fair value of the warrants were valued on the date of grant at $112 using the Black-Scholes option-pricing model with the following parameters: (1) risk-free interest rate of 1.43%; (2) expected life in years of 3.0; (3) expected stock volatility of 74.82%; and (4) expected dividend yield of 0%. The Company recorded $28 and $47 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss in relation to the consulting agreement for the three and six months ended June 30, 2020, respectively. The Company recorded $0 and $9 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss in relation to the consulting agreement for the three and six months ended June 30, 2021, respectively. On January 20, 2021, the Company entered into a services agreement with a service provider whereby it agreed to issue warrants to purchase an aggregate 340,020 shares of common stock of the Company with an exercise price equal to $1.75 per share of common stock, which will vest over a one-year period on a monthly basis and will have an exercise period of three years from the date of issuance. The fair value of the warrants were valued on the date of grant at $355 using the Black-Scholes option-pricing model with the following parameters: (1) risk-free interest rate of 0.19%; (2) expected life in years of 3.0; (3) expected stock volatility of 100.99%; and (4) expected dividend yield of 0%. The Company recorded $89 and $148 as general and administrative expense in the accompanying consolidated statement of comprehensive loss in relation to the consulting agreement for the three and six months ended June 30, 2021, respectively. On August 28, 2020 the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) under which it sold and issued to an institutional investor (the “Holder”), in a registered direct offering, an aggregate of 3,200,000 shares of the Company’s common stock par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase an aggregate of 5,533,625 shares of Common Stock (the “Pre-Funded Warrants”) at an exercise price of $0.001 per share. 2021, the Pre-Funded Warrants for 5,533,625 shares of common stock exercised Pursuant to the Securities Purchase Agreement, as described above, in a concurrent private placement, the Company also agreed to issue to the purchaser warrants to purchase up to 8,733,625 shares of Common Stock (the “Private Placement Warrants”). These warrants were immediately exercisable at an exercise price of $1.30 per share and expire on the fifth anniversary of the date of issuance. In connection with the Exercise Agreement, the Company entered into a financial advisory agreement (the “Letter Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. acted as exclusive financial advisor to the Company in this transaction and received a cash fee of $300 upon full cash exercise of the Private Placement Warrants, which was included in financing fees in the consolidated statement of shareholders’ equity, as of June 30, 2021. As additional compensation, A.G.P. will receive a cash fee equal to $200 upon the cash exercise in full of the New Warrants. Warrants A summary of the Company’s warrants to purchase common stock activity is as follows: Shares Weighted Weighted Aggregate Outstanding and exercisable at December 31, 2020 17,058,051 $ 1.86 5.78 $ - Granted 6,340,020 2.10 Exercised (14,267,250 ) 1.24 - Outstanding at June 30, 2021 9,130,821 $ 3.00 3.44 $ - As of June 30, 2021, 8,932,491 warrants were exercisable. Stock Options 2016 Equity Incentive Plan In December 2016, the Company adopted the Motus GI Holdings, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s board of directors may grant options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock, stock units, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards to employees, officers, directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the 2016 Plan, the number of shares of common stock available for issuance under the 2016 Plan shall increase annually by six percent (6%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year; provided, however, that the board of directors may act prior to the first day of any calendar year to provide that there shall be no increase such calendar year, or that the increase shall be a lesser number of shares of the Company’s common stock than would otherwise occur. On January 1, 2021, pursuant to an annual evergreen provision, the number of shares of common stock reserved for future grants was increased by 1,936,669 shares. Under the 2016 Plan, effective as of January 1, 2021, the maximum number of shares of the Company’s common stock authorized for issuance is 7,592,663. As of June 30, 2021, there were 261,863 shares of common stock available for future grant under the 2016 Plan. A summary of the Company’s stock option activity is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 5,029,119 $ 3.00 7.96 $ - Granted 1,166,500 1.74 Forfeited (159,400 ) 3.53 Outstanding at June 30, 2021 6,036,219 $ 2.75 8.02 $ - The Company estimated the fair value of each stock option award using the Black-Scholes option pricing model based on the following weighted average assumptions: Six months Ended 2021 2020 Expected term, in years 5.75 5.8 Expected volatility 106.76 % 79.59 % Risk-free interest rate 0.73 % 1.49 % Dividend yield - - Grant date fair value $ 1.74 $ 0.95 As of June 30, 2021, unamortized share-based compensation for stock options was $2,354, with a weighted-average recognition period of 1.04 years. As of June 30, 2021, outstanding options to purchase 3,637,864 shares of common stock were exercisable with a weighted-average exercise price per share of $3.43. For the three and six months ended June 30, 2021, the Company recorded $680 and $1,349, respectively, for share based compensation expense related to stock options. For the three and six months ended June 30, 2020, the Company recorded $498 and $1,180, respectively, for share based compensation expense related to stock options. Restricted Stock Units On February 17, 2021, the Company’s Compensation Committee approved the issuance of 160,000 restricted stock unit awards to non-employee directors which vest on the first anniversary of the date of grant, and 266,000 restricted stock unit awards, to executives which vest over a three-year period on a quarterly basis. The aggregate fair value of the restricted stock unit awards granted was estimated to be $758 using the market price of the stock on the date of the grant which is expensed using the straight-line method over a one to three-year period. The Company recorded $241 and $423 as general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021, respectively, in relation to the aggregate 927,266 restricted stock units issued to date to the CEO, executives, and directors. A summary of the Company’s restricted stock unit awards activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Nonvested at December 31, 2020 337,927 $ 3.10 Granted 426,000 1.78 Vested (118,996 ) 2.74 Nonvested at June 30, 2021 644,929 $ 2.30 As of June 30, 2021, unamortized share compensation for restricted stock units was $1,233, with a weighted-average recognition period of 0.99 years. Share-based Compensation The following table sets forth total non-cash share-based compensation for the issuance of options to purchase common stock, warrants to purchase common stock, and restricted stock unit award by operating statement classification for the three and six months ended June 30, 2021 and 2020: Three Months ended Six Months ended 2021 2020 2021 2020 Research and development $ 169 $ 114 $ 303 $ 337 Sales and marketing 105 44 222 172 General and administrative 736 495 1,404 948 Total $ 1,010 $ 653 $ 1,929 $ 1,457

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Events Term Loan Refinancing On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $12,000 (the “Loan”) in three tranches as follows: (a) on the Effective Date, a loan in the aggregate principal amount of $4,000 (the “Convertible Bullet Loan”), (b) on the Effective Date, a loan in the aggregate principal amount of $5,000 (“Tranche B”), and (c) available until December 31, 2021, a loan in the aggregate principal amount of $3,000 (“Tranche C”, together with the Convertible Bullet Loan and Tranche B, the “Loan” or “Loans”). The Convertible Bullet Loan and Tranche B were funded on the Effective Date. The Convertible Bullet Loan requires forty-eight monthly interest only payments commencing after the Effective Date and thereafter full payment of the then outstanding principal balance of the Bullet Loan on July 1, 2025. The Tranche B loan requires interest only monthly payments commencing on the Effective Date until September 30, 2022 and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025. The Tranche C loan, to the extent drawn on or prior to December 31, 2021, requires monthly payments of interest only commencing on the date drawn until September 30, 2022 and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025. Notwithstanding the foregoing, in the event the Borrower completes a capital raise of a minimum of $20,000 prior to September 30, 2022, the repayment terms of the Tranche B and Tranche C loans shall automatically be amended so that the interest only period will be extended to June 30, 2023, and, thereafter, the Borrower shall pay twenty-four monthly payments of principal and interest accrued thereon until June 1, 2025. Interest on the Convertible Bullet Loan accrues at 7.75% per annum. Interest on the Tranche B and Tranche C loans accrues at 9.5% per annum. The Loan Agreement contains customary representations and warranties, indemnification provisions in favor of Lender, events of default and affirmative and negative covenants, including, among others, covenants that limit or restrict the Company’s ability to, among other things, incur additional indebtedness, merge or consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make investments, dispose of assets and enter into certain transactions with affiliates, in each case subject to certain exceptions. There are no liquidity or financial covenants. In connection with the Kreos Loan Agreement, the Company also issued to Lender a warrant (“Warrant”), dated July 16, 2021, to purchase up to 190,949 shares of the Company’s common stock, at an exercise price of $1.0474 per share, payable in cash or on a cashless basis according to the formula set forth in the Warrant. The exercise price of the Warrant and the number of shares issuable upon exercise of the Warrant are subject to adjustments for stock splits, combinations, stock dividends or similar events. The Warrant is exercisable until the date that is ten years after the date of issuance. On the Effective Date, the Company used a portion of the proceeds from the Loan to repay in full all amounts outstanding under, and discharge all obligations in respect of, the Loan Agreement, between the Company and Silicon Valley Bank. The payment amount of approximately $8,200 included a negotiated prepayment premium of $220 under the terms of the payoff arrangement with Silicon Valley Bank.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the six months ended June 30, 2021 are consistent with those discussed in Note 3 to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2021.
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue recognition	Revenue recognition Sales contracts executed for the second generation Pure-Vu System are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled to. The Pure-Vu System consists of a Workstation and single use disposable sleeves (“Disposables”). For contracts outside the scope of ASC 606, the Company determines income for proposed supply arrangements under 1) ASC 842 as it pertains to an embedded lease of the Workstation within a proposed supply arrangement and 2) ASC 606 for the sale of the Disposables within the proposed supply arrangement. The Company allocates the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier. During the three months ended June 30, 2021, the Company recognized revenue of $100, which primarily consisted of $72 in accordance with ASC 606 and $28 in accordance with ASC 842. During the three months ended June 30, 2020, the Company recognized revenue of $1 in accordance with ASC 606. During the six months ended June 30, 2021, the Company recognized revenue of $151, which primarily consisted of $108 in accordance with ASC 606 and $43 in accordance with ASC 842. During the six months ended June 30, 2020, the Company recognized revenue of $29 in accordance with ASC 606.
Basic and diluted net loss per share	Basic and diluted net loss per share Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period. Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend for the issuance of warrants during the three and six months ended June 30, 2021 of $0 and $6,145, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders.
Income taxes	Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2021, and December 31, 2020, the Company had a full valuation allowance against its deferred tax assets. For the three and six months ended June 30, 2021 and 2020, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and six months ended June 30, 2021 and 2020, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its consolidated financial statements and disclosures. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”, or ASU 2019-12, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was adopted on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company’s financial position or results of operations.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s financial statements and disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of fair value of financial assets and liabilities	June 30, 2021 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,734 $ 1,734 December 31, 2020 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,617 $ 1,617
Schedule of estimated fair value of level 3 contingent royalty obligation	Fair Value Measurements of Contingent Royalty Obligation (Level 3) Balance at December 31, 2020 $ 1,617 Change in estimated fair value of contingent royalty obligation 117 Balance at June 30, 2021 $ 1,734

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	June 30, December 31, Raw materials $ 273 $ 333 Work-in-process - 211 Finished goods 682 529 Inventory reserve (249 ) (268 ) Inventory, net $ 706 $ 805

Fixed Assets, Net (Tables)

Fixed Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of fixed assets, net	June 30, December 31, Office equipment $ 168 $ 167 Computers and software 303 299 Machinery 775 455 Lab and medical equipment 1,186 1,039 Leasehold improvements 186 185 Total 2,618 2,145 Less: accumulated depreciation and amortization (1,167 ) (967 ) Fixed assets, net $ 1,451 $ 1,178

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of lease cost and supplemental balance sheet information	Three Months ended Six Months ended 2021 2020 2021 2020 Lease Cost Operating lease cost, net of related party license fee $ 32 $ 50 $ 64 $ 105 Variable lease cost 30 29 60 58 Total lease cost $ 62 $ 79 $ 124 $ 163 As of As of 2021 2020 Assets Operating lease, right-of-use- asset $ 712 $ 766 Liabilities Current Operating lease liabilities $ 261 $ 238 Non-current Operating lease liabilities, net of current portion 467 547 Total lease liabilities $ 728 $ 785 Other information: Weighted average remaining lease term - operating leases 2.89 years 3.33 years Weighted-average discount rate - operating leases 7.65 % 7.78 %

Term Debt (Tables)

Term Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of future maturities of term debt	Years Ending December 31, Amount 2021 (remaining six months) $ - 2022 2,000 2023 4,000 2024 2,000 Total 8,000 Less unamortized debt issuance costs (17 ) Total Term Debt, less debt issuance costs $ 7,983

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of warrants	Shares Weighted Weighted Aggregate Outstanding and exercisable at December 31, 2020 17,058,051 $ 1.86 5.78 $ - Granted 6,340,020 2.10 Exercised (14,267,250 ) 1.24 - Outstanding at June 30, 2021 9,130,821 $ 3.00 3.44 $ -
Schedule of stock option activity	Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 5,029,119 $ 3.00 7.96 $ - Granted 1,166,500 1.74 Forfeited (159,400 ) 3.53 Outstanding at June 30, 2021 6,036,219 $ 2.75 8.02 $ -
Schedule of option pricing model using weighted average assumptions	Six months Ended 2021 2020 Expected term, in years 5.75 5.8 Expected volatility 106.76 % 79.59 % Risk-free interest rate 0.73 % 1.49 % Dividend yield - - Grant date fair value $ 1.74 $ 0.95
Schedule of restricted stock unit awards activity	Number of Shares Weighted Average Grant Date Fair Value Nonvested at December 31, 2020 337,927 $ 3.10 Granted 426,000 1.78 Vested (118,996 ) 2.74 Nonvested at June 30, 2021 644,929 $ 2.30
Schedule of stock-based compensation	Three Months ended Six Months ended 2021 2020 2021 2020 Research and development $ 169 $ 114 $ 303 $ 337 Sales and marketing 105 44 222 172 General and administrative 736 495 1,404 948 Total $ 1,010 $ 653 $ 1,929 $ 1,457

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020		Dec. 31, 2019
Basis Of Presentation And Going Concerns [Abstract]
Accumulated deficit	$ (113,112)		$ (113,112)		$ (103,721)
Total current assets	28,017		28,017
Total current liabilities	10,401		10,401
Working capital	17,616		17,616
Net loss	(4,742)	$ (4,410)	(9,391)	$ (10,921)
Cash and cash equivalents	26,379	$ 17,125	26,379	$ 17,125	$ 20,819	[1]	$ 20,528
Unrestricted cash	$ 10,000		$ 10,000
[1]	Derived from audited consolidated financial statements

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Summary of Significant Accounting Policies (Details) [Line Items]
Recognized revenue, description		the Company recognized revenue of $100, which primarily consisted of $72 in accordance with ASC 606 and $28 in accordance with ASC 842. During the three months ended June 30, 2020, the Company recognized revenue of $1 in accordance with ASC 606. During the six months ended June 30, 2021, the Company recognized revenue of $151, which primarily consisted of $108 in accordance with ASC 606 and $43 in accordance with ASC 842. During the six months ended June 30, 2020, the Company recognized revenue of $29 in accordance with ASC 606.
Deemed dividends from warrant issuance	$ 0
Warrant [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Deemed dividends from warrant issuance		$ 6,145,000

Fair Value Measurements (Detail

Fair Value Measurements (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurements (Details) [Line Items]
Fair value of the liability, description	the Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $204 and a 2% increase in the discount rate would decrease the liability by approximately $144.
Discount Rate [Member]
Fair Value Measurements (Details) [Line Items]
Increase (Decrease) in discount rate	21.00%	21.00%
Royalty payment, percentage	3.00%	3.00%

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of fair value of financial assets and liabilities - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Contingent royalty obligation	$ 1,734	$ 1,617
Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Contingent royalty obligation
Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Contingent royalty obligation
Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Contingent royalty obligation	$ 1,734	$ 1,617

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of estimated fair value of level 3 contingent royalty obligation - Fair Value Measurements of Contingent Royalty Obligation (Level 3) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value Measurements (Details) - Schedule of estimated fair value of level 3 contingent royalty obligation [Line Items]
Balance at beginning	$ 1,617
Change in estimated fair value of contingent royalty obligation	117
Balance at ending	$ 1,734

Inventory (Details)

Inventory (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventory write-down charge	$ 0	$ 0	$ 0	$ 0

Inventory (Details) - Schedule

Inventory (Details) - Schedule of inventory - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of inventory [Abstract]
Raw materials	$ 273	$ 333
Work-in-process		211
Finished goods	682	529
Inventory reserve	(249)	(268)
Inventory, net	$ 706	$ 805	[1]
[1]	Derived from audited consolidated financial statements

Fixed Assets, Net (Details)

Fixed Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 102		$ 200	$ 201
Depreciation and amortization expenses		$ 125		201
Incurred loss impairment of fixed assets		$ 9		$ 18

Fixed Assets, Net (Details) - S

Fixed Assets, Net (Details) - Schedule of fixed assets, net - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 2,618	$ 2,145
Less: accumulated depreciation and amortization	(1,167)	(967)
Fixed assets, net	1,451	1,178
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	168	167
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	303	299
Machinery [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	775	455
Lab and medical equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	1,186	1,039
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 186	$ 185

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases (Details) [Line Items]
Operating lease, expense	$ 62		$ 124
License fee	$ 47	$ 44	$ 94	$ 79
General and Administrative Expense [Member]
Leases (Details) [Line Items]
Operating lease, expense		$ 79		$ 163
Florida [Member] | Office [Member]
Leases (Details) [Line Items]
Term of expires Date			November 2024
Percentage of increase in annual base rent			2.75%
Israel [Member] | Office [Member]
Leases (Details) [Line Items]
Percentage of increase in annual base rent			4.00%
Expire date			Dec. 31, 2022
Renewal Term	3 years		3 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease cost and supplemental balance sheet information - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Lease Cost
Operating lease cost, net of related party license fee	$ 32	$ 50	$ 64	$ 105
Variable lease cost	30	29	60	58
Total lease cost	62	$ 79	124	$ 163
Assets
Operating lease, right-of-use- asset	712		712		$ 766	[1]
Current
Operating lease liabilities	261		261		238	[1]
Non-current
Operating lease liabilities, net of current portion	467		467		547	[1]
Total lease liabilities	$ 728		$ 728		$ 785
Other information:
Weighted average remaining lease term - operating leases	2 years 10 months 20 days		2 years 10 months 20 days		3 years 3 months 29 days
Weighted-average discount rate - operating leases	7.65%		7.65%		7.78%
[1]	Derived from audited consolidated financial statements

Term Debt (Details)

Term Debt (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Jul. 16, 2021	Jan. 02, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 13, 2019
Term Debt (Details) [Line Items]
Term debt							$ 8,000
Term debt, description		Principal payments will commence July 1, 2022 and continuing for 24 consecutive months thereafter. The Company may prepay all, but not less than all, of the outstanding principal balance of the Term Debt subject to prepayment premium of $240, plus all other sums, if any, that shall have become due and payable.			The Term Debt of $8,000 bears an interest rate equal to the greater of (i) one-half of one percent (0.50%) above the Prime Rate and (ii) five and one-half percent (5.50%). At June 30, 2021, the interest rate was 5.50%. The Term Debt is collateralized by substantially all assets of the Company. Additionally, the Company has pledged 65% of the outstanding capital stock in the Company’s foreign subsidiary, Motus GI Medical Technologies, Ltd., to collateralize the Term Debt.
Debt issuance costs					$ 50
Amortized to interest expense			$ 2,000		4,000
Debt issuance costs				$ 2	$ 4	$ 21
Effective interest rate on the term debt			5.69%		5.69%
Bank least					$ 10,000
Subsequent Event [Member]
Term Debt (Details) [Line Items]
Negotiated prepayment premium	$ 12,000
Amount of payment	8,200
Negotiated prepayment premium	$ 220

Term Debt (Details) - Schedule

Term Debt (Details) - Schedule of future maturities of term debt $ in Thousands	Dec. 31, 2021USD ($)
Schedule of future maturities of term debt [Abstract]
2021 (remaining six months)
2022	2,000
2023	4,000
2024	2,000
Total	8,000
Less unamortized debt issuance costs	(17)
Total Term Debt, less debt issuance costs	$ 7,983

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Commitments and Contingencies (Details) [Line Items]
Royalty received			$ 1,332
Description of royalty payment			LIBOR interest to date in the amount of $1,413 and $1,407 as of June 30, 2021 and December 31, 2020, respectively. This obligation is repaid in the form of royalties on revenues generated in any fashion from know-how developed using IIA grants, with a rate that is currently 4% (which may be increased under certain circumstances), up to 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grants received, plus interest at the rate of 12-month LIBOR.
Licensing proceeds	$ 3,500		$ 3,500
Contingent royalty obligation			1,734		$ 1,617
Gain on change in fair value of contingent royalty obligation	$ 37	$ 77	117	$ 245
Severance payments			$ 1,408
Royalty Payment Rights on Royalty Payment Rights Certificates [Member]
Commitments and Contingencies (Details) [Line Items]
Description of royalty payment			the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of: ●3% of net sales subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the Company’s 2017 private placement (the “2017 Private Placement”); and  ●5% of licensing proceeds subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the 2017 Private Placement.
Initial Licensing Proceeds Milestone [Member]
Commitments and Contingencies (Details) [Line Items]
Royalty received			$ 30,000
Series A Convertible Preferred Stock [Member]
Commitments and Contingencies (Details) [Line Items]
Percentage of payment amount			10.00%
Series A Convertible Preferred Stock [Member] | Royalty Payment Rights on Royalty Payment Rights Certificates [Member]
Commitments and Contingencies (Details) [Line Items]
Description of royalty payment			●3% of Net Sales* for commercialized product directly; and ●5% of any Licensing Proceeds** for rights to commercialize the product if sublicensed by the Company to a third-party.  *Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $20,000 (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Net Sales” is defined in the Royalty Payment Rights Certificates.

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Jan. 31, 2020
Related Party Transactions (Details) [Line Items]
License fee	$ 47,000	$ 44	$ 94,000	$ 79
Shared Space Agreements [Member]
Related Party Transactions (Details) [Line Items]
Percentage of holder of common stock						5.00%
Related party receivable			2,000		$ 0
Shareholder Loan [Member] | Minimum [Member]
Related Party Transactions (Details) [Line Items]
License fee			162,000
Shareholder Loan [Member] | Maximum [Member]
Related Party Transactions (Details) [Line Items]
License fee			$ 198,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)

Jan. 13, 2021

Feb. 06, 2020

Jun. 22, 2021

May 17, 2021

Apr. 30, 2021

Mar. 31, 2021

Feb. 17, 2021

Jan. 27, 2021

Jan. 20, 2021

Aug. 28, 2020

Jun. 30, 2021

Mar. 31, 2021

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Stock-Based Compensation (Details) [Line Items]

Accrued expenses

$ 56,000

Weighted average grant date fair value (in Dollars per share)

$ 1.08

Granted (in Shares)

426,000

Share price (in Dollars per share)

$ 1.06

Share based compensation expense related to stock option

$ 680,000

$ 498,000

$ 1,349,000

$ 1,180,000

Aggregate offering price

$ 25,000,000

Pursuant share of common stock (in Shares)

1,340,870

Net cash proceeds

$ 1,826,000

Issuance costs

$ 74,000

Aggregate share of common stock (in Shares)

50,000

Expense related to consulting agreement

$ 53

$ 53

Number of warrants purchased (in Shares)

8,733,625

8,733,625

Exercise price (in Dollars per share)

$ 1.30

Exercise price (in Dollars per share)

$ 3

$ 3

$ 1.86

Risk-free interest rate

0.73%

1.49%

Expected life in years

5 years 9 months

5 years 9 months 18 days

Expected stock volatility percentage

106.76%

79.59%

Expected dividend yields percentage

Services agreement, description

The Company recorded $28 and $47 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss in relation to the consulting agreement for the three and six months ended June 30, 2020, respectively. The Company recorded $0 and $9 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss in relation to the consulting agreement for the three and six months ended June 30, 2021, respectively.

The fair value of the warrants were valued on the date of grant at $355 using the Black-Scholes option-pricing model with the following parameters: (1) risk-free interest rate of 0.19%; (2) expected life in years of 3.0; (3) expected stock volatility of 100.99%; and (4) expected dividend yield of 0%. The Company recorded $89 and $148 as general and administrative expense in the accompanying consolidated statement of comprehensive loss in relation to the consulting agreement for the three and six months ended June 30, 2021, respectively.

Securities purchase agreement, description

the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) under which it sold and issued to an institutional investor (the “Holder”), in a registered direct offering, an aggregate of 3,200,000 shares of the Company’s common stock par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase an aggregate of 5,533,625 shares of Common Stock (the “Pre-Funded Warrants”) at an exercise price of $0.001 per share. During the three and six months ended June 30, 2021, the Pre-Funded Warrants for 5,533,625 shares of common stock were exercised which resulted in aggregate proceeds of $0 and $6.

Warrants outstanding (in Shares)

9,130,821

9,130,821

17,058,051

Due to exercise units (in Shares)

733,625

Cash paid payment per share (in Dollars per share)

$ 0.10

Number warrant issued (in Shares)

600,000

Received gross proceeds before expenses

$ 11,000

Outstanding private placement warrants (in Shares)

8,000,000

Exercisable and expire term

5 years

Fair alue adjustment of warrants, shares (in Shares)

6,000,000

Fair value warrants amount

$ 6,745,000

Expected dividend yields

0.00%

Deemed dividend

$ 6,145,000

Cash fees

300,000

Warrants exercisable (in Shares)

8,932,491

Description of incentive plan

On January 1, 2021, pursuant to an annual evergreen provision, the number of shares of common stock reserved for future grants was increased by 1,936,669 shares. Under the 2016 Plan, effective as of January 1, 2021, the maximum number of shares of the Company’s common stock authorized for issuance is 7,592,663. As of June 30, 2021, there were 261,863 shares of common stock available for future grant under the 2016 Plan.

Unamortized share-based compensation for stock options

$ 2,354,000

Weighted-average recognition period

1 year 14 days

Outstanding options to purchase,shares of common stock were exercisable (in Shares)

3,637,864

3,637,864

Weighted-average exercise price per share (in Dollars per share)

$ 3.43

$ 3.43

Restricted stock unit (in Shares)

160,000

Restricted stock units (in Shares)

266,000

Restricted Stock Units (RSUs) [Member]

Stock-Based Compensation (Details) [Line Items]

Unamortized share-based compensation for stock options

$ 1,233,000

Weighted-average recognition period

11 months 26 days

Restricted stock units (in Shares)

927,266

Restricted stock unit awards granted

$ 758,000

General and administrative expense

$ 241,000

$ 423,000

Private Placement [Member]

Stock-Based Compensation (Details) [Line Items]

Private placement warrants shares (in Shares)

8,000,000

Private Placement [Member] | Exercise Agreement [Member]

Stock-Based Compensation (Details) [Line Items]

Warrants outstanding (in Shares)

8,000,000

Executives and Employees [Member]

Stock-Based Compensation (Details) [Line Items]

Number of shares issued (in Shares)

52,317

Director [Member]

Stock-Based Compensation (Details) [Line Items]

Number of shares issued (in Shares)

18,209

Granted (in Shares)

121,237

Share price (in Dollars per share)

$ 1.04

$ 1.78

Cash compensation for service

$ 19,000

$ 216,000

Prepaid compensation amount

$ 121,000

Share based compensation expense related to stock option

$ 60,000

$ 114,000

Minimum [Member]

Stock-Based Compensation (Details) [Line Items]

Expected life in years

4 years 11 months 12 days

Risk free interest rates minimum

0.41%

Expected stock volatilities percentage minimum

103.00%

Maximum [Member]

Stock-Based Compensation (Details) [Line Items]

Risk free interest rates maximum

0.57%

Expected stock volatilities percentage maximum

103.23%

Common Stock [Member]

Stock-Based Compensation (Details) [Line Items]

Exercised, shares (in Shares)

1,340,870

14,267,250

Percentage of number of shares

6.00%

6.00%

Restricted stock unit (in Shares)

53,081

65,915

30,916

15,070

Common Stock [Member] | Services Agreement [Member]

Stock-Based Compensation (Details) [Line Items]

Number of warrants purchased (in Shares)

120,000

Warrant term

3 years

Warrant [Member] | Services Agreement [Member]

Stock-Based Compensation (Details) [Line Items]

Granted (in Shares)

60,000

Number of warrants purchased (in Shares)

340,020

Warrant term

3 years

Exercise price (in Dollars per share)

$ 2.16

Remaining warrants granted (in Shares)

60,000

Exercise price (in Dollars per share)

$ 3.50

$ 1.75

Fair value of warrants share

$ 112,000

Risk-free interest rate

1.43%

Expected life in years

3 years

Expected stock volatility percentage

74.82%

Expected dividend yields percentage

0.00%

New Warrants [Member]

Stock-Based Compensation (Details) [Line Items]

Gross proceeds before expenses (in Shares)

6,000,000

Exercised, shares (in Shares)

8,000,000

Cash excercise

$ 200,000

New Warrants [Member] | Private Placement [Member]

Stock-Based Compensation (Details) [Line Items]

Exercise price (in Dollars per share)

$ 2.12

Warrants outstanding (in Shares)

6,000,000

Purchase warrant per share (in Dollars per share)

$ 0.75

New Warrants [Member] | Private Placement [Member] | Exercise Agreement [Member]

Stock-Based Compensation (Details) [Line Items]

Warrants outstanding (in Shares)

8,000,000

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of warrants	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Schedule of warrants [Abstract]
Shares Underlying Warrants Outstanding at Beginning | shares	17,058,051
Weighted Average Exercise Price Outstanding at Beginning | $ / shares	$ 1.86
Weighted Average Remaining Contractual Life (years) Outstanding at Beginning	5 years 9 months 10 days
Aggregate Intrinsic Value, Outstanding at Beginning | $
Shares Underlying Warrants Granted | shares	6,340,020
Weighted Average Exercise Price Granted | $ / shares	$ 2.10
Shares Underlying Warrants Exercised | shares	(14,267,250)
Weighted Average Exercise Price Exercised | $ / shares	$ 1.24
Shares Underlying Warrants Outstanding at Ending | shares	9,130,821
Weighted Average Exercise Price Outstanding at Ending | $ / shares	$ 3
Weighted Average Remaining Contractual Life (years) Outstanding at Ending	3 years 5 months 8 days
Aggregate Intrinsic Value, Outstanding at Ending | $

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of stock option activity	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Schedule of stock option activity [Abstract]
Shares Underlying Options, Outstanding Beginning | shares	5,029,119
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 3
Weighted Average Remaining Contractual Life (years), Outstanding Beginning	7 years 11 months 15 days
Aggregate Intrinsic Value, Outstanding Beginning | $
Shares Underlying Options, Granted | shares	1,166,500
Weighted Average Exercise Price, Granted | $ / shares	$ 1.74
Shares Underlying Options, Forfeited | shares	(159,400)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 3.53
Shares Underlying Options, Outstanding Ending | shares	6,036,219
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 2.75
Weighted Average Remaining Contractual Life (years), Outstanding Ending	8 years 7 days
Aggregate Intrinsic Value, Outstanding Ending | $

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of option pricing model using weighted average assumptions - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Schedule of option pricing model using weighted average assumptions [Abstract]
Expected term, in years	5 years 9 months	5 years 9 months 18 days
Expected volatility	106.76%	79.59%
Risk-free interest rate	0.73%	1.49%
Dividend yield
Grant date fair value (in Dollars per share)	$ 1.74	$ 0.95

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details) - Schedule of restricted stock unit awards activity	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Schedule of restricted stock unit awards activity [Abstract]
Number of Shares Nonvested Beginning | shares	337,927
Weighted Average Grant Date Fair Value Nonvested Beginning | $ / shares	$ 3.10
Number of Shares Granted | shares	426,000
Weighted Average Grant Date Fair Value Granted | $ / shares	$ 1.78
Number of Shares Vested | shares	(118,996)
Weighted Average Grant Date Fair Value Vested | $ / shares	$ 2.74
Number of Shares Nonvested Ending | shares	644,929
Weighted Average Grant Date Fair Value Nonvested Ending | $ / shares	$ 2.30

Stock-Based Compensation (Det_6

Stock-Based Compensation (Details) - Schedule of stock-based compensation - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Stock-Based Compensation (Details) - Schedule of stock-based compensation [Line Items]
Total	$ 1,010	$ 653	$ 1,929	$ 1,457
Research and development [Member]
Stock-Based Compensation (Details) - Schedule of stock-based compensation [Line Items]
Total	169	114	303	337
Sales and marketing [Member]
Stock-Based Compensation (Details) - Schedule of stock-based compensation [Line Items]
Total	105	44	222	172
General and administrative [Member]
Stock-Based Compensation (Details) - Schedule of stock-based compensation [Line Items]
Total	$ 736	$ 495	$ 1,404	$ 948

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	1 Months Ended
	Jul. 16, 2021USD ($)$ / shares
Subsequent Events (Details) [Line Items]
Aggregate principal amount	$ 12,000,000
Term loan refinancing, description	The Convertible Bullet Loan requires forty-eight monthly interest only payments commencing after the Effective Date and thereafter full payment of the then outstanding principal balance of the Bullet Loan on July 1, 2025. The Tranche B loan requires interest only monthly payments commencing on the Effective Date until September 30, 2022 and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025. The Tranche C loan, to the extent drawn on or prior to December 31, 2021, requires monthly payments of interest only commencing on the date drawn until September 30, 2022 and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025. Notwithstanding the foregoing, in the event the Borrower completes a capital raise of a minimum of $20,000 prior to September 30, 2022, the repayment terms of the Tranche B and Tranche C loans shall automatically be amended so that the interest only period will be extended to June 30, 2023, and, thereafter, the Borrower shall pay twenty-four monthly payments of principal and interest accrued thereon until June 1, 2025.
Purchase shares of Company’s common stock	$ 190,949
Exercise price (in Dollars per share) | $ / shares	$ 1.0474
Warrant is exercisable, term	10 years
Existing indebtedness	$ 8,200,000
Negotiated prepayment premium	220,000
Convertible Bullet Loan [Member]
Subsequent Events (Details) [Line Items]
Aggregate principal amount	4,000,000
Tranche B [Member]
Subsequent Events (Details) [Line Items]
Aggregate principal amount	$ 5,000,000
Loan accrues rate, percentage	7.75%
Tranche C [Member]
Subsequent Events (Details) [Line Items]
Aggregate principal amount	$ 3,000,000
Loan accrues rate, percentage	9.50%